NASDAQ:SCMP - Sucampo Pharmaceuticals Stock Price, Price Target & More

$18.05 +0.05 (+0.28 %)
(As of 04/20/2018 06:36 AM ET)
Previous Close$18.00
Today's Range$18.05 - $18.05
52-Week Range$9.30 - $18.75
Volume303,068 shs
Average Volume2.56 million shs
Market Capitalization$839.46 million
P/E RatioN/A
Dividend YieldN/A
Beta1.38

About Sucampo Pharmaceuticals (NASDAQ:SCMP)

Sucampo Pharmaceuticals logoSucampo Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product. VTS-270 is an investigational drug under clinical study for the treatment of Niemann-Pick Disease Type C-1, an ultra-orphan, progressive and fatal disease. AMITIZA is a ClC-2 chloride channel activator, which has been approved for three indications that cover distinct patient types: chronic idiopathic constipation, irritable bowel syndrome with constipation, and opioid-induced constipation. RESCULA is a Big Potassium channel activator used to lower intraocular pressure. CPP-1X/sulindac combination product is meant for the treatment of familial adenomatous polyposis (FAP).

Receive SCMP News and Ratings via Email

Sign-up to receive the latest news and ratings for SCMP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryPharmaceuticals
SectorN/A
SymbolNASDAQ:SCMP
CUSIP86490910
Phone+1-301-9613400

Debt

Debt-to-Equity Ratio7.37%
Current Ratio5.11%
Quick Ratio4.46%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E Ratio16.12
P/E Growth5.06

Sales & Book Value

Annual Sales$230.06 million
Price / Sales3.70
Cash Flow$2.4163 per share
Price / Cash7.47
Book Value$3.60 per share
Price / Book5.01

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$18.48 million
Net Margins16.92%
Return on Equity126.04%
Return on Assets11.04%

Miscellaneous

Employees139
Outstanding Shares47,170,000

How to Become a New Pot Stock Millionaire

Sucampo Pharmaceuticals (NASDAQ:SCMP) Frequently Asked Questions

What is Sucampo Pharmaceuticals' stock symbol?

Sucampo Pharmaceuticals trades on the NASDAQ under the ticker symbol "SCMP."

How were Sucampo Pharmaceuticals' earnings last quarter?

Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) released its quarterly earnings data on Wednesday, November, 1st. The biopharmaceutical company reported $0.27 EPS for the quarter, beating the consensus estimate of $0.25 by $0.02. The biopharmaceutical company earned $61.27 million during the quarter, compared to the consensus estimate of $58.05 million. Sucampo Pharmaceuticals had a return on equity of 126.04% and a net margin of 16.92%. The firm's revenue for the quarter was up 5.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.30 EPS. View Sucampo Pharmaceuticals' Earnings History.

What price target have analysts set for SCMP?

9 brokers have issued 12 month target prices for Sucampo Pharmaceuticals' stock. Their forecasts range from $11.00 to $43.00. On average, they anticipate Sucampo Pharmaceuticals' share price to reach $21.5556 in the next twelve months. View Analyst Ratings for Sucampo Pharmaceuticals.

What are Wall Street analysts saying about Sucampo Pharmaceuticals stock?

Here are some recent quotes from research analysts about Sucampo Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Sucampo’s pending acquisition by Mallinckrodt for $1.2 billion have raised investor concerns that the latter may be underpaying for the company. A sNDA for label expansion of Amitizia in pediatric functional constipation is under review. Also, Sucampo’s collaborations with firms like Takeda and Mylan for Amitiza’s commercialization is a big positive. Moreover, the Vtesse acquisition added a pivotal program in Niemann-Pick Disease type C1 to its pipeline. However, Sucampo’s dependence on Amitiza for growth is concerning with few companies trying to market and sell generic version of Amitiza. Moreover, Sucampo discontinued Amitzia’s sprinkle formulation development as it did not meet bioequivalence with capsule formulation. Shares of the company have outperformed the industry. Estimates have remained stable ahead of the Q4 earnings results. The company has a mixed record of earnings surprises in recent quarters." (2/9/2018)
  • 2. Maxim Group analysts commented, "Sucampo’s stock has risen sharply in the past few weeks (from ~$10 to $16+) on no new fundamental news. However, a Bloomberg story has been circulating that the company may be entertaining suitors. We have no specific knowledge to confirm this, but do see an undervalued company that is generating free cash flow and has a strong (orphan) pipeline. Our last note (from 11/21) reviewed the R&D Day which focused on two key pipeline products, VTS-270 (Neeman Pick Disease) and CPP-1X/sulindac (Familial Adenomatous Polyposis )." (12/7/2017)

Who are some of Sucampo Pharmaceuticals' key competitors?

Who are Sucampo Pharmaceuticals' key executives?

Sucampo Pharmaceuticals' management team includes the folowing people:
  • Peter S. Greenleaf, Chairman of the Board, Chief Executive Officer (Age 47)
  • Peter P. Pfreundschuh CPA, Chief Financial Officer (Age 48)
  • Max Donley, Executive Vice President of Global Human Resources, Information Technology and Strategy (Age 48)
  • Matthias Alder, Executive Vice President (Age 52)
  • Peter A. Kiener Ph.D., Chief Scientific Officer (Age 64)
  • Alex Driggs, General Counsel, Corporate Secretary (Age 41)
  • Peter Lichtlen M.D., Ph.D., Chief Medical Officer (Age 47)
  • John H. Johnson, Lead Independent Director (Age 58)
  • Paul R. Edick, Director (Age 62)
  • Daniel P. Getman Ph.D., Director (Age 59)

Has Sucampo Pharmaceuticals been receiving favorable news coverage?

Media headlines about SCMP stock have been trending somewhat positive on Friday, according to Accern Sentiment. The research group identifies negative and positive media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Sucampo Pharmaceuticals earned a media sentiment score of 0.22 on Accern's scale. They also assigned news headlines about the biopharmaceutical company an impact score of 45.89 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

How do I buy shares of Sucampo Pharmaceuticals?

Shares of SCMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sucampo Pharmaceuticals' stock price today?

One share of SCMP stock can currently be purchased for approximately $18.05.

How big of a company is Sucampo Pharmaceuticals?

Sucampo Pharmaceuticals has a market capitalization of $839.46 million and generates $230.06 million in revenue each year. Sucampo Pharmaceuticals employs 139 workers across the globe.

How can I contact Sucampo Pharmaceuticals?

Sucampo Pharmaceuticals' mailing address is 805 King Farm Blvd Ste 550, ROCKVILLE, MD 20850-6162, United States. The biopharmaceutical company can be reached via phone at +1-301-9613400 or via email at [email protected]


MarketBeat Community Rating for Sucampo Pharmaceuticals (SCMP)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  266 (Vote Outperform)
Underperform Votes:  230 (Vote Underperform)
Total Votes:  496
MarketBeat's community ratings are surveys of what our community members think about Sucampo Pharmaceuticals and other stocks. Vote "Outperform" if you believe SCMP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SCMP will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Sucampo Pharmaceuticals (NASDAQ:SCMP) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
9 Wall Street analysts have issued ratings and price targets for Sucampo Pharmaceuticals in the last 12 months. Their average twelve-month price target is $21.5556, suggesting that the stock has a possible upside of 19.42%. The high price target for SCMP is $43.00 and the low price target for SCMP is $11.00. There are currently 7 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldBuy
Consensus Rating Score: 2.222.222.402.71
Ratings Breakdown: 0 Sell Rating(s)
7 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $21.5556$21.5556$23.40$17.2857
Price Target Upside: 19.42% upside20.29% upside28.93% upside68.64% upside

Sucampo Pharmaceuticals (NASDAQ:SCMP) Consensus Price Target History

Price Target History for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Sucampo Pharmaceuticals (NASDAQ:SCMP) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/26/2018NomuraReiterated RatingBuy -> Neutral$18.00LowView Rating Details
1/5/2018UBSDowngradeBuy -> Neutral$18.00LowView Rating Details
1/3/2018MizuhoReiterated RatingNeutral -> Neutral$14.00 -> $18.00LowView Rating Details
1/2/2018Leerink SwannReiterated RatingOutperform -> Market Perform$15.00LowView Rating Details
1/1/2018Maxim GroupDowngradeHoldLowView Rating Details
12/26/2017B. RileyDowngradeBuy -> Neutral$18.00LowView Rating Details
12/19/2017InstinetInitiated CoverageBuy$43.00HighView Rating Details
8/3/2017Roth CapitalSet Price TargetBuy$30.00MediumView Rating Details
5/4/2017Jefferies GroupLower Price TargetHold$13.00 -> $11.00MediumView Rating Details
3/10/2017WallachBeth CapitalLower Price TargetBuy$20.00 -> $15.00LowView Rating Details
9/7/2016Northland SecuritiesInitiated CoverageOutperform$15.00N/AView Rating Details
5/4/2016GuggenheimReiterated RatingBuy$29.00N/AView Rating Details
(Data available from 4/20/2016 forward)

Earnings

Sucampo Pharmaceuticals (NASDAQ:SCMP) Earnings History and Estimates Chart

Earnings by Quarter for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Sucampo Pharmaceuticals (NASDAQ:SCMP) Earnings Estimates

2018 EPS Consensus Estimate: $1.15
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$0.26$0.26$0.26
Q2 20181$0.24$0.24$0.24
Q3 20181$0.28$0.28$0.28
Q4 20181$0.37$0.37$0.37

Sucampo Pharmaceuticals (NASDAQ SCMP) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2017Q3 2017$0.25$0.27$58.05 million$61.27 millionViewN/AView Earnings Details
8/2/2017Q2 2017$0.22$0.28$56.44 million$59.90 millionViewListenView Earnings Details
5/3/2017Q1 2017$0.28$0.23$54.15 million$56.30 millionViewListenView Earnings Details
3/8/2017Q4 2016$0.48$0.68$66.00 million$73.00 millionViewListenView Earnings Details
11/9/2016Q316$0.26$0.28$51.30 million$57.90 millionViewListenView Earnings Details
8/3/2016Q216$0.22$0.23$48.33 million$52.00 millionViewListenView Earnings Details
5/4/2016Q116$0.19$0.21$44.11 million$47.20 millionViewListenView Earnings Details
3/8/2016Q415$0.19$0.43$42.72 million$55.40 millionViewListenView Earnings Details
11/4/2015Q315$0.18$0.16$36.18 million$33.50 millionViewListenView Earnings Details
8/5/2015Q215$0.15$0.21$31.90 million$34.90 millionViewListenView Earnings Details
5/6/2015Q114$0.14$0.14$30.19 million$29.50 millionViewListenView Earnings Details
3/4/2015Q413$0.17$0.21$37.23 million$37.80 millionViewListenView Earnings Details
11/6/2014Q313$0.04$0.03$26.11 million$31.50 millionViewListenView Earnings Details
8/5/2014Q213$0.03$0.04$24.06 million$24.10 millionViewListenView Earnings Details
5/7/2014Q113$0.04$0.02$24.19 million$22.20 millionViewListenView Earnings Details
2/26/2014Q4($0.04)$0.06$22.75 million$24.50 millionViewListenView Earnings Details
11/5/2013Q3 2013($0.03)$0.09$20.47 million$21.16 millionViewN/AView Earnings Details
8/8/2013Q2 2013$0.11$0.14$27.96 million$27.02 millionViewN/AView Earnings Details
5/7/2013Q1 2013($0.09)($0.08)$17.91 million$16.92 millionViewN/AView Earnings Details
3/13/2013Q4 2012$0.12$0.32$32.21 million$34.90 millionViewListenView Earnings Details
11/8/2012Q3 2012($0.07)($0.14)ViewN/AView Earnings Details
8/7/2012Q2 2012($0.02)ViewN/AView Earnings Details
5/9/2012Q1 2012($0.05)ViewN/AView Earnings Details
3/13/2012Q4 2011($0.11)ViewN/AView Earnings Details
11/3/2011Q3 2011($0.10)ViewN/AView Earnings Details
8/4/2011Q2 2011($0.22)ViewN/AView Earnings Details
5/10/2011Q1 2011($0.17)ViewN/AView Earnings Details
3/3/2011Q4 2010($0.01)($0.15)ViewN/AView Earnings Details
11/3/2010Q3 2010($0.05)$0.06ViewN/AView Earnings Details
8/5/2010Q2 2010($0.01)($0.05)ViewN/AView Earnings Details
5/10/2010Q1 2010($0.01)ViewN/AView Earnings Details
3/15/2010Q4 2009$0.02$0.03ViewN/AView Earnings Details
8/6/2009Q2 2009($0.01)($0.01)ViewN/AView Earnings Details
5/7/2009Q1 2009$0.02($0.04)ViewN/AView Earnings Details
2/19/2009Q4 2008($0.06)($0.07)ViewN/AView Earnings Details
11/12/2008Q3 2008$0.01($0.06)ViewN/AView Earnings Details
8/14/2008Q2 2008$0.62$0.71ViewN/AView Earnings Details
5/8/2008Q1 2008($0.01)$0.01ViewN/AView Earnings Details
3/11/2008Q4 2007($0.02)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Sucampo Pharmaceuticals (NASDAQ:SCMP) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Sucampo Pharmaceuticals (NASDAQ SCMP) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.13%
Institutional Ownership Percentage: 67.09%
Insider Trading History for Sucampo Pharmaceuticals (NASDAQ:SCMP)
Institutional Ownership by Quarter for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Sucampo Pharmaceuticals (NASDAQ SCMP) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/7/2017Peter A KienerInsiderSell50,000$16.50$825,000.0052,023View SEC Filing  
9/11/2017Sachiko KunoMajor ShareholderSell1,000,000$12.00$12,000,000.00View SEC Filing  
9/6/2017Jason Patrick MeyenburgInsiderBuy4,000$12.13$48,520.0030,228View SEC Filing  
8/4/2017Jones W BryanInsiderBuy4,700$10.60$49,820.004,700View SEC Filing  
11/29/2016Daniel P GetmanDirectorSell20,000$16.86$337,200.0016,201View SEC Filing  
11/29/2016Peter GreenleafCEOSell200,000$16.84$3,368,000.00120,054View SEC Filing  
11/28/2016Matthias AlderEVPSell150,000$16.00$2,400,000.0029,449View SEC Filing  
11/15/2016Andrew P SmithCFOSell1,766$15.58$27,514.28348View SEC Filing  
8/28/2015Daniel P. GetmanDirectorSell30,000$28.14$844,200.00View SEC Filing  
7/20/2015Thomas J KnappInsiderSell64,528$23.43$1,511,891.04View SEC Filing  
3/12/2015William AshtonDirectorSell55,762$17.55$978,623.10View SEC Filing  
3/11/2015Anthony C CelesteDirectorSell65,966$17.34$1,143,850.44View SEC Filing  
12/16/2014Cary J ClaiborneCFOSell50,000$12.91$645,500.00View SEC Filing  
12/15/2014Cary J ClaiborneCFOSell7,100$12.89$91,519.00View SEC Filing  
8/7/2014Sachiko KunoMajor ShareholderSell181,727$6.28$1,141,245.56View SEC Filing  
8/4/2014Ryuji UenoMajor ShareholderSell140,873$6.02$848,055.46View SEC Filing  
7/31/2014S&R Technology Holdings, LlcMajor ShareholderSell100$6.25$625.00View SEC Filing  
7/30/2014S&R Technology Holdings, LlcMajor ShareholderSell300$6.25$1,875.00View SEC Filing  
7/25/2014Ryuji UenoMajor ShareholderSell16,155$6.26$101,130.30View SEC Filing  
7/23/2014Ryuji UenoMajor ShareholderSell5,845$6.29$36,765.05View SEC Filing  
7/22/2014S&R Technology Holdings, LlcMajor ShareholderSell2,500$6.25$15,625.00View SEC Filing  
7/21/2014S&R Technology Holdings, LlcMajor ShareholderSell100$6.25$625.00View SEC Filing  
7/18/2014S&R Technology Holdings, LlcMajor ShareholderSell15,000$6.27$94,050.00View SEC Filing  
4/29/2014S&R Technology Holdings, Llcmajor shareholderSell113,600$6.65$755,440.0022,820,802View SEC Filing  
4/25/2014Sachiko Kunomajor shareholderSell118,700$6.69$794,103.0060,357View SEC Filing  
3/18/2014Gayle DolecekDirectorSell1,200$8.03$9,636.00View SEC Filing  
2/27/2014Cary ClaiborneCFOSell2,500$9.00$22,500.00View SEC Filing  
1/17/2014Ryuji UenoCEOSell360,000$10.36$3,729,600.00148,530View SEC Filing  
1/7/2014Cary ClaiborneCFOSell2,500$9.00$22,500.00View SEC Filing  
10/16/2013Sachiko KunoMajor ShareholderSell360,000$6.35$2,286,000.00View SEC Filing  
9/18/2013Ryuji UenoCEOSell38,462$5.69$218,848.78148,530View SEC Filing  
9/3/2013Ryuji UenoCEOSell38,462$5.59$215,002.58148,530View SEC Filing  
8/19/2013Ryuji UenoCEOSell38,462$6.04$232,310.48148,530View SEC Filing  
8/6/2013Sachiko Kunomajor shareholderSell38,462$6.21$238,849.0260,357View SEC Filing  
7/24/2013Ryuji UenoCEOSell38,462$6.52$250,772.24View SEC Filing  
7/9/2013S&R Technology Holdings, LlcMajor ShareholderSell38,462$6.48$249,233.76View SEC Filing  
6/24/2013S&R Technology Holdings, LlcMajor ShareholderSell38,462$6.61$254,233.82View SEC Filing  
6/10/2013Sachiko KunoMajor ShareholderSell38,462$7.29$280,387.98View SEC Filing  
5/28/2013Ryuji UenoCEOSell38,462$8.79$338,080.98View SEC Filing  
5/21/2013Cary J ClaiborneCFOSell4,640$9.52$44,172.80View SEC Filing  
5/20/2013Stanley G MieleSVPSell6,400$9.60$61,440.00View SEC Filing  
5/16/2013Stanley G MieleSVPSell48,600$9.67$469,962.00View SEC Filing  
5/15/2013Timothy I MaudlinDirectorBuy32,870$9.82$322,783.40View SEC Filing  
5/13/2013Sachiko KunoMajor ShareholderSell38,462$9.27$356,542.74View SEC Filing  
2/4/2013S&R Technology Holdings, LlcMajor ShareholderSell38,462$5.22$200,771.64View SEC Filing  
12/26/2012S&R Technology Holdings, LlcMajor ShareholderSell20,262$5.01$101,512.62View SEC Filing  
11/27/2012Sachiko KunoMajor ShareholderSell12,205$5.00$61,025.00View SEC Filing  
11/13/2012Sachiko KunoMajor ShareholderSell11,962$5.00$59,810.00View SEC Filing  
11/1/2012Sachiko KunoMajor ShareholderSell37,595$5.06$190,230.70View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Sucampo Pharmaceuticals (NASDAQ SCMP) News Headlines

Source:
DateHeadline
Sucampo Pharmaceuticals (SCMP) Downgraded by TheStreet to "D"Sucampo Pharmaceuticals (SCMP) Downgraded by TheStreet to "D"
www.americanbankingnews.com - April 13 at 10:15 AM
Sucampo Pharmaceuticals, Inc. (SCMP) Given Consensus Rating of "Hold" by BrokeragesSucampo Pharmaceuticals, Inc. (SCMP) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - April 5 at 3:08 AM
Sucampo Pharmaceuticals (SCMP) Buy Rating Reaffirmed at Maxim GroupSucampo Pharmaceuticals' (SCMP) Buy Rating Reaffirmed at Maxim Group
www.americanbankingnews.com - April 1 at 11:24 PM
Sucampo Pharmaceuticals (SCMP) Lowered to "Hold" at Maxim GroupSucampo Pharmaceuticals (SCMP) Lowered to "Hold" at Maxim Group
www.americanbankingnews.com - March 31 at 2:06 PM
Sucampo Pharmaceuticals (SCMP) "Neutral" Rating Reaffirmed at MizuhoSucampo Pharmaceuticals' (SCMP) "Neutral" Rating Reaffirmed at Mizuho
www.americanbankingnews.com - March 31 at 12:46 AM
Medivation (MDVN) versus Sucampo Pharmaceuticals (SCMP) Head to Head ComparisonMedivation (MDVN) versus Sucampo Pharmaceuticals (SCMP) Head to Head Comparison
www.americanbankingnews.com - March 28 at 3:16 PM
Cerecor Appoints Peter Greenleaf as Chief Executive OfficerCerecor Appoints Peter Greenleaf as Chief Executive Officer
finance.yahoo.com - March 28 at 9:24 AM
Financial Review: Sucampo Pharmaceuticals (SCMP) and Kythera Biopharmaceuticals (KYTH)Financial Review: Sucampo Pharmaceuticals (SCMP) and Kythera Biopharmaceuticals (KYTH)
www.americanbankingnews.com - March 25 at 5:17 AM
Sucampo Pharmaceuticals, Inc. (SCMP) Receives Average Rating of "Hold" from AnalystsSucampo Pharmaceuticals, Inc. (SCMP) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - March 11 at 5:33 AM
150,000 Shares in Sucampo Pharmaceuticals, Inc. (SCMP) Acquired by Water Island Capital LLC150,000 Shares in Sucampo Pharmaceuticals, Inc. (SCMP) Acquired by Water Island Capital LLC
www.americanbankingnews.com - March 2 at 9:50 PM
Sucampo Pharmaceuticals (SCMP) Scheduled to Post Quarterly Earnings on TuesdaySucampo Pharmaceuticals (SCMP) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - February 27 at 2:34 AM
58,840 Shares in Sucampo Pharmaceuticals, Inc. (SCMP) Purchased by Virtu Financial LLC58,840 Shares in Sucampo Pharmaceuticals, Inc. (SCMP) Purchased by Virtu Financial LLC
www.americanbankingnews.com - February 25 at 2:32 PM
Analyzing Sucampo Pharmaceuticals (SCMP) and Kura Oncology (KURA)Analyzing Sucampo Pharmaceuticals (SCMP) and Kura Oncology (KURA)
www.americanbankingnews.com - February 23 at 5:12 AM
BidaskClub Downgrades Sucampo Pharmaceuticals (SCMP) to BuyBidaskClub Downgrades Sucampo Pharmaceuticals (SCMP) to Buy
www.americanbankingnews.com - February 18 at 1:00 PM
Sucampo Pharmaceuticals, Inc. (SCMP) Receives Average Rating of "Buy" from BrokeragesSucampo Pharmaceuticals, Inc. (SCMP) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - February 14 at 3:34 AM
Sucampo Pharmaceuticals (SCMP) Downgraded by Zacks Investment Research to HoldSucampo Pharmaceuticals (SCMP) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - February 9 at 8:58 PM
Quotidian Technical Highlights on Selected Drug Makers Stocks -- Novo Nordisk, Sucampo Pharma, Synergy Pharma, and Teva Pharmaceutical IndustriesQuotidian Technical Highlights on Selected Drug Makers Stocks -- Novo Nordisk, Sucampo Pharma, Synergy Pharma, and Teva Pharmaceutical Industries
www.bizjournals.com - February 9 at 9:24 AM
ValuEngine Upgrades Sucampo Pharmaceuticals (SCMP) to "Strong-Buy"ValuEngine Upgrades Sucampo Pharmaceuticals (SCMP) to "Strong-Buy"
www.americanbankingnews.com - February 4 at 2:19 PM
Barclays: Mallinckrodts Sucampo Deal Overshadowed By Competitive ThreatsBarclays: Mallinckrodt's Sucampo Deal Overshadowed By Competitive Threats
finance.yahoo.com - February 3 at 9:14 AM
Sucampo Pharmaceuticals, Inc. (SCMP) Expected to Announce Quarterly Sales of $75.59 MillionSucampo Pharmaceuticals, Inc. (SCMP) Expected to Announce Quarterly Sales of $75.59 Million
www.americanbankingnews.com - February 3 at 2:36 AM
$0.34 EPS Expected for Sucampo Pharmaceuticals, Inc. (SCMP) This Quarter$0.34 EPS Expected for Sucampo Pharmaceuticals, Inc. (SCMP) This Quarter
www.americanbankingnews.com - February 1 at 7:22 PM
Sucampo Pharmaceuticals (SCMP) Lifted to Buy at Zacks Investment ResearchSucampo Pharmaceuticals (SCMP) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - February 1 at 11:12 AM
Sucampo Pharmaceuticals (SCMP) Downgraded by Zacks Investment ResearchSucampo Pharmaceuticals (SCMP) Downgraded by Zacks Investment Research
www.americanbankingnews.com - January 31 at 1:12 PM
Monteverde & Associates PC Files Class Action Lawsuit On Behalf Of Shareholders Of Sucampo Pharmaceuticals, Inc. In The District Of MarylandMonteverde & Associates PC Files Class Action Lawsuit On Behalf Of Shareholders Of Sucampo Pharmaceuticals, Inc. In The District Of Maryland
finance.yahoo.com - January 26 at 9:27 AM
Sucampo Pharmaceuticals (SCMP) Rating Reiterated by NomuraSucampo Pharmaceuticals (SCMP) Rating Reiterated by Nomura
www.americanbankingnews.com - January 26 at 8:46 AM
SUCAMPO PHARMACEUTICALS (SCMP) SHAREHOLDER ALERT – Andrews & Springer LLC Is Investigating Sucampo Pharmaceuticals, Inc. for Potential Breaches of Fiduciary DutySUCAMPO PHARMACEUTICALS (SCMP) SHAREHOLDER ALERT – Andrews & Springer LLC Is Investigating Sucampo Pharmaceuticals, Inc. for Potential Breaches of Fiduciary Duty
finance.yahoo.com - January 22 at 6:03 PM
Lifshitz & Miller LLP Announces Investigation of Advanced Micro Devices, Aflac Incorporated, DST Systems, Inc., Forum Merger Corporation, GoPro, Inc., Sucampo Pharmaceuticals, Inc. and ZAIS Group Holdings, Inc.Lifshitz & Miller LLP Announces Investigation of Advanced Micro Devices, Aflac Incorporated, DST Systems, Inc., Forum Merger Corporation, GoPro, Inc., Sucampo Pharmaceuticals, Inc. and ZAIS Group Holdings, Inc.
www.prnewswire.com - January 21 at 1:46 AM
Sucampo Pharmaceuticals, Inc. (SCMP) Receives Average Recommendation of "Buy" from BrokeragesSucampo Pharmaceuticals, Inc. (SCMP) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - January 20 at 3:38 AM
$75.59 Million in Sales Expected for Sucampo Pharmaceuticals, Inc. (SCMP) This Quarter$75.59 Million in Sales Expected for Sucampo Pharmaceuticals, Inc. (SCMP) This Quarter
www.americanbankingnews.com - January 17 at 2:40 AM
Sucampo Pharmaceuticals, Inc. (SCMP) Expected to Announce Earnings of $0.34 Per ShareSucampo Pharmaceuticals, Inc. (SCMP) Expected to Announce Earnings of $0.34 Per Share
www.americanbankingnews.com - January 15 at 9:14 PM
Aradigm's Bronchiectasis Candidate Has Negative FDA VoteAradigm's Bronchiectasis Candidate Has Negative FDA Vote
finance.yahoo.com - January 12 at 3:33 PM
Perrigo (PRGO) Hits 52-Week High: What's Driving the Stock?Perrigo (PRGO) Hits 52-Week High: What's Driving the Stock?
finance.yahoo.com - January 12 at 11:23 AM
Sucampo Pharmaceuticals (SCMP) Cut to "Neutral" at UBS GroupSucampo Pharmaceuticals (SCMP) Cut to "Neutral" at UBS Group
www.americanbankingnews.com - January 7 at 8:37 AM
Sucampo Pharmaceuticals, Inc. (SCMP) Expected to Post FY2019 Earnings of $1.79 Per ShareSucampo Pharmaceuticals, Inc. (SCMP) Expected to Post FY2019 Earnings of $1.79 Per Share
www.americanbankingnews.com - January 5 at 6:34 PM
Are Options Traders Betting on a Big Move in Sucampo (SCMP) Stock?Are Options Traders Betting on a Big Move in Sucampo (SCMP) Stock?
finance.yahoo.com - January 5 at 11:12 AM
Celsion's Phase I/II Cancer Study Initiation Gets FDA NodCelsion's Phase I/II Cancer Study Initiation Gets FDA Nod
finance.yahoo.com - January 5 at 11:12 AM
Omeros Inks Agreement With FDA for OMS721 Phase III TrialOmeros Inks Agreement With FDA for OMS721 Phase III Trial
finance.yahoo.com - January 4 at 11:17 AM
Wolf Popper LLP Investigates the Proposed Acquisition of Sucampo Pharmaceuticals, Inc. by Mallinckrodt plc - PR Newswire (press release)Wolf Popper LLP Investigates the Proposed Acquisition of Sucampo Pharmaceuticals, Inc. by Mallinckrodt plc - PR Newswire (press release)
www.prnewswire.com - January 2 at 8:51 PM
Wolf Popper LLP Investigates the Proposed Acquisition of Sucampo Pharmaceuticals, Inc. by Mallinckrodt plcWolf Popper LLP Investigates the Proposed Acquisition of Sucampo Pharmaceuticals, Inc. by Mallinckrodt plc
finance.yahoo.com - January 2 at 11:10 AM
Sucampo Pharmaceuticals (SCMP) Rating Reiterated by Leerink SwannSucampo Pharmaceuticals (SCMP) Rating Reiterated by Leerink Swann
www.americanbankingnews.com - January 2 at 8:48 AM
SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Sucampo Pharmaceuticals, Inc ... - PR Newswire (press release)SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Sucampo Pharmaceuticals, Inc ... - PR Newswire (press release)
www.prnewswire.com - January 1 at 3:35 PM
Sucampo Pharmaceuticals (SCMP) Upgraded at ValuEngineSucampo Pharmaceuticals (SCMP) Upgraded at ValuEngine
www.americanbankingnews.com - January 1 at 11:22 AM
SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Sucampo Pharmaceuticals, Inc. -- SCMPSHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Sucampo Pharmaceuticals, Inc. -- SCMP
finance.yahoo.com - January 1 at 11:07 AM
SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Sucampo Pharmaceuticals, Inc. - SCMPSHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Sucampo Pharmaceuticals, Inc. - SCMP
finance.yahoo.com - December 29 at 10:51 AM
Sucampo Pharmaceuticals, Inc. (SCMP) Sees Large Increase in Short InterestSucampo Pharmaceuticals, Inc. (SCMP) Sees Large Increase in Short Interest
www.americanbankingnews.com - December 29 at 1:58 AM
CORRECTING and REPLACING Investor Alert: Levi & Korsinsky, LLP Notifies Investors of an Investigation Concerning Whether the Sale of Sucampo Pharmaceuticals, Inc. to Mallinckrodt plc is Fair to ShareholdersCORRECTING and REPLACING Investor Alert: Levi & Korsinsky, LLP Notifies Investors of an Investigation Concerning Whether the Sale of Sucampo Pharmaceuticals, Inc. to Mallinckrodt plc is Fair to Shareholders
finance.yahoo.com - December 28 at 3:10 PM
Wired News - Mallinckrodt to Acquire Sucampo PharmaceuticalsWired News - Mallinckrodt to Acquire Sucampo Pharmaceuticals
finance.yahoo.com - December 28 at 8:53 AM
Mallinckrodt to Buy Sucampo Pharmaceuticals for About $840 MillionMallinckrodt to Buy Sucampo Pharmaceuticals for About $840 Million
www.wsj.com - December 27 at 6:11 PM
Mallinckrodt International Finance SA -- Moodys places Mallinckrodts ratings under review for downgrade following Sucampo announcementMallinckrodt International Finance SA -- Moody's places Mallinckrodt's ratings under review for downgrade following Sucampo announcement
finance.yahoo.com - December 27 at 6:11 PM
Analyst: Why The Sucampo Deal Is A Smart Move For MallinckrodtAnalyst: Why The Sucampo Deal Is A Smart Move For Mallinckrodt
finance.yahoo.com - December 27 at 6:11 PM

SEC Filings

Sucampo Pharmaceuticals (NASDAQ:SCMP) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Sucampo Pharmaceuticals (NASDAQ:SCMP) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Sucampo Pharmaceuticals (NASDAQ SCMP) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.